


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) None	Entity Type
0001553643	Camp Nine, Inc.	• Corporation
Name of Issuer	CAMP NINE, INC.	C Limited Partnership
RELMADA THERAPEUTICS, INC.		C Limited Liability Company
Jurisdiction of Incorporation/Organization	•	C General Partnership
NEVADA		C Business Trust
Year of Incorporation/Organization	o n	C Other
⋄ Over Five Years Ago		
C Within Last Five Years (Specify Year)		
C Yet to Be Formed		





Relationship:	П	Execut	ive Officer	V	Director		Promoter	
Clarification of Response (if Necessary)								
Chairman of the Board			<u></u>					
								_
Last Name			First Name			Middle	Name	
Kelly			Paul					
Street Address 1				6	Street Address 2	7		
880 Third Avenue					12th Floor			
City			State/Province/	ا Coun	trv	ZIP/Pos	tal Code	
New York			NEW YORK			10022		
I TOTAL			1,2,, 10111			10022		
Relationship:	П	Execut	ive Officer	V	Director		Promoter	
Clarification of Response	(if No	cessarv	·)					
or response	(22 2 11	, cessur y	,					
								_
Last Name			First Name			Middle	Name	
Shenouda			Maged]		
Street Address 1					Street Address 2	Ц		
880 Third Avenue				[12th Floor			
City			State/Province/	Coun		7IP/Pos	tal Code	
New York			NEW YORK				10022	
			1,2,, 10111			10022		
Relationship:	П	Execut	ive Officer	V	Director		Promoter	
Clarification of Response (if Necessary)								
			,					
								_
Last Name			First Name			Middle	Name	
Vitolo			Ottavio			1		
Street Address 1					Street Address 2	П		
880 Third Avenue				[12th Floor			
City			State/Province/	Coun		ZIP/Pos	tal Code	
New York			NEW YORK	Coun		10022	tai Couc	
TW TORK			NEW TORK			10022		
Relationship:	V	Exposit	ive Officer	_	Director		Promoter	
Relationship:	12	EACCUI	ive Officer				Promoter	
Clarification of Response	(if No	ecessary	·)					
Chief Medical Officer								

4. Industry Group

~ A	griculture	Hea	lth Care	O	Retailing
	anking & Financial Services	7020	Biotechnology		
	Commercial Banking	0	Health Insurance Hospitals & Physicians	O	Restaurants
	Insurance	0	Pharmaceuticals		Technology
- 6	Investing	0	Other Health Care		C Computers
-	Investment Banking				C Telecommunications
-	Pooled Investment Fund				C Other Technology
-	Other Banking & Financial Services				Travel
C 10	Susiness Services	Mai	nufacturing		C Airlines & Airports
	nergy	Rea	l Estate Commercial		C Lodging & Conventions
	Coal Mining	0	Construction		C Tourism & Travel Services
	Electric Utilities	O	REITS & Finance		C Other Travel
	Energy Conservation Environmental Services	O	Residential	C	Other
	Oil & Gas	O	Other Real Estate		
	Other Energy				
5. 1	ssuer Size				
	nue Range		Aggregate Net Asset		
•	No Revenues		0.40		et Asset Value
0	\$1 - \$1,000,000		\$1 - \$5,000,0		
0	\$1,000,001 - \$5,000,000		\$5,000,001 -		
0	\$5,000,001 - \$25,000,000		\$25,000,001		
0	\$25,000,001 - \$100,000,000		\$50,000,001		
C	Over \$100,000,000		O Over \$100,00		
C	Decline to Disclose		C Decline to Di		se
C	Not Applicable		O Not Applicat	ole	
6. I	Federal Exemption(s) a	nd	Exclusion(s) Clain	ne	d (select all that
apı	oly)				
П	Rule 504(b)(1) (not (i), (ii) or (iii))	Г	Rule 505		
П	Rule 504 (b)(1)(i)	-	Rule 506(b)		
П	Rule 504 (b)(1)(ii)	Г			
П	Rule 504 (b)(1)(iii)	Г	Rule 506(c)		
10.000	Kuie 304 (b)(1)(iii)		Securities Act Section 4(a)(5)		
		1	Investment Company Act Sec	tion	1 3(c)
7.	Type of Filing				
V	New Notice Date of First Sale	20	19-05-14	First	t Sale Yet to Occur
П	Amendment				
8. I	Ouration of Offering				
Does	the Issuer intend this offering to last mo	re th	nan one year?	0	Yes © No
			-		
9.	Type(s) of Securities Of	fer	ed (select all that	ар	ply)
	Pooled Investment Fund Interests	quity			
10.00	1	ebt			

	rant or Other Right to ther Security	
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other Right to Acquire	ibe)	
10. Business Combination Trans	action	
Is this offering being made in connection with a busines transaction, such as a merger, acquisition or exchange of		No
Clarification of Response (if Necessary)		
4.4. Minimovino Investigant		
11. Minimum Investment Minimum investment accepted from any outside	10000	LICD
investor \$	10000	USD
12. Sales Compensation		
Recipient	Recipient CRD Number	None
Alexander Capital, LP	40077	
(Associated) Broker or Dealer None	(Associated) Broker or Deale Number	er CRD None
Street Address 1	Street Address 2	
17 STATE STREET	5TH FLOOR	
	ate/Province/Country	ZIP/Postal Code
	NEW YORK	10004
State(s) of Solicitation All States	Foreign/Non-US	
ARIZONA		
CALIFORNIA		
GEORGIA GEORGIA		
MARYLAND		
NEVADA		
NEW JERSEY		
NEW YORK		
SOUTH CAROLINA		
WYOMING		
		70.57
Recipient	Recipient CRD Number	None
Brookline Capital Markets, A division of CIM Securities, LLC	120852	
(Associated) Broker or Dealer None	(Associated) Broker or Deale Number	er CRD None
Street Address 1	Street Address 2	
509 MADISON AVENUE, SUITE 906		
	ate/Province/Country	ZIP/Postal Code
NEW YORK	NEW YORK	10022
State(s) of Solicitation	Foreign/Non-US	

-
ALABAMA
CALIFORNIA
FLORIDA
MARYLAND
NEVADA
NEW JERSEY
NEW YORK
ОНЮ
SOUTH CAROLINA
TEXAS
WYOMING

13. Offering and Sales Amounts					
Total Offering Amount \$ 10000000 □ Indefinite					
Total Amount Sold \$ 3414505 USD					
Total Remaining to be \$ 6585495 USD ☐ Indefinite					
Clarification of Response (if Necessary)					
14. Investors					
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total					
number of investors who already have invested in the offering:					
15. Sales Commissions & Finders' Fees Expenses					
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.					
Sales Commissions \$ 221150 USD Estimate					
Finders' Fees \$ 0 USD Estimate					

16. Use of Proceeds

Clarification of Response (if Necessary)

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

Alexander Capital and Brookline received a cash fee (excluding expenses) of \$72,650 and \$148,500, respectively, and warrants to purchase an aggregate of 147,433 shares of common stock.

\$ 0 USD Estimate

In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
RELMADA THERAPEUTICS, INC.	/s/ Sergio Traversa	Sergio Traversa	CEO	2019-05-16